Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens.

Bosseboeuf A, Feron D, Tallet A, Rossi C, Charlier C, Garderet L, Caillot D, Moreau P, Cardó-Vila M, Pasqualini R, Arap W, Nelson AD, Wilson BS, Perreault H, Piver E, Weigel P, Girodon F, Harb J, Bigot-Corbel E, Hermouet S.

JCI Insight. 2017 Oct 5;2(19). pii: 95367. doi: 10.1172/jci.insight.95367. [Epub ahead of print]

2.

BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.

Lewis VO, Devarajan E, Cardó-Vila M, Thomas DG, Kleinerman ES, Marchiò S, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8065-8070. doi: 10.1073/pnas.1704173114. Epub 2017 Jul 11.

3.

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.

Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG 2nd, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12786-12791. doi: 10.1073/pnas.1615400113. Epub 2016 Oct 24.

4.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12780-12785. doi: 10.1073/pnas.1615288113. Epub 2016 Oct 24.

5.

Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity.

Cardó-Vila M, Marchiò S, Sato M, Staquicini FI, Smith TL, Bronk JK, Yin G, Zurita AJ, Sun M, Behrens C, Sidman RL, Lee JJ, Hong WK, Wistuba II, Arap W, Pasqualini R.

Am J Pathol. 2016 Aug;186(8):2162-2170. doi: 10.1016/j.ajpath.2016.04.013. Epub 2016 Jun 16.

6.

AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas.

Smith TL, Yuan Z, Cardó-Vila M, Sanchez Claros C, Adem A, Cui MH, Branch CA, Gelovani JG, Libutti SK, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):2466-71. doi: 10.1073/pnas.1525709113. Epub 2016 Feb 16.

7.

Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors.

Dondossola E, Dobroff AS, Marchiò S, Cardó-Vila M, Hosoya H, Libutti SK, Corti A, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2223-8. doi: 10.1073/pnas.1525697113. Epub 2016 Feb 8.

8.

Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release.

Hosoya H, Dobroff AS, Driessen WH, Cristini V, Brinker LM, Staquicini FI, Cardó-Vila M, D'Angelo S, Ferrara F, Proneth B, Lin YS, Dunphy DR, Dogra P, Melancon MP, Stafford RJ, Miyazono K, Gelovani JG, Kataoka K, Brinker CJ, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):1877-82. doi: 10.1073/pnas.1525796113. Epub 2016 Feb 2.

9.

The peptidomimetic Vasotide targets two retinal VEGF receptors and reduces pathological angiogenesis in murine and nonhuman primate models of retinal disease.

Sidman RL, Li J, Lawrence M, Hu W, Musso GF, Giordano RJ, Cardó-Vila M, Pasqualini R, Arap W.

Sci Transl Med. 2015 Oct 14;7(309):309ra165. doi: 10.1126/scitranslmed.aac4882.

10.

PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8403-8. doi: 10.1073/pnas.1507882112. Epub 2015 Jun 15.

11.

Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.

Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W.

Cancer. 2015 Jul 15;121(14):2411-21. doi: 10.1002/cncr.29344. Epub 2015 Apr 1.

12.

Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens.

Karjalainen K, Jaalouk DE, Bueso-Ramos C, Bover L, Sun Y, Kuniyasu A, Driessen WH, Cardó-Vila M, Rietz C, Zurita AJ, O'Brien S, Kantarjian HM, Cortes JE, Calin GA, Koivunen E, Arap W, Pasqualini R.

Clin Cancer Res. 2015 Jul 1;21(13):3041-51. doi: 10.1158/1078-0432.CCR-13-3059. Epub 2015 Mar 16.

13.

Synchronous down-modulation of miR-17 family members is an early causative event in the retinal angiogenic switch.

Nunes DN, Dias-Neto E, Cardó-Vila M, Edwards JK, Dobroff AS, Giordano RJ, Mandelin J, Brentani HP, Hasselgren C, Yao VJ, Marchiò S, Pereira CA, Passetti F, Calin GA, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3770-5. doi: 10.1073/pnas.1500008112. Epub 2015 Mar 9.

14.

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3776-81. doi: 10.1073/pnas.1500128112. Epub 2015 Mar 11.

15.

Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer.

Mintz PJ, Rietz AC, Cardó-Vila M, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2515-20. doi: 10.1073/pnas.1500097112. Epub 2015 Feb 9.

16.

Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice.

Rotolo J, Stancevic B, Zhang J, Hua G, Fuller J, Yin X, Haimovitz-Friedman A, Kim K, Qian M, Cardó-Vila M, Fuks Z, Pasqualini R, Arap W, Kolesnick R.

J Clin Invest. 2012 May;122(5):1786-90. doi: 10.1172/JCI59920. Epub 2012 Apr 2.

17.

Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients.

Staquicini FI, Cardó-Vila M, Kolonin MG, Trepel M, Edwards JK, Nunes DN, Sergeeva A, Efstathiou E, Sun J, Almeida NF, Tu SM, Botz GH, Wallace MJ, O'Connell DJ, Krajewski S, Gershenwald JE, Molldrem JJ, Flamm AL, Koivunen E, Pentz RD, Dias-Neto E, Setubal JC, Cahill DJ, Troncoso P, Do KA, Logothetis CJ, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18637-42. doi: 10.1073/pnas.1114503108. Epub 2011 Nov 2.

18.

From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway.

Cardó-Vila M, Giordano RJ, Sidman RL, Bronk LF, Fan Z, Mendelsohn J, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5118-23. doi: 10.1073/pnas.0915146107. Epub 2010 Feb 26.

19.

From combinatorial peptide selection to drug prototype (I): targeting the vascular endothelial growth factor receptor pathway.

Giordano RJ, Cardó-Vila M, Salameh A, Anobom CD, Zeitlin BD, Hawke DH, Valente AP, Almeida FC, Nör JE, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5112-7. doi: 10.1073/pnas.0915141107. Epub 2010 Feb 26.

20.

Processing of the matricellular protein hevin in mouse brain is dependent on ADAMTS4.

Weaver MS, Workman G, Cardo-Vila M, Arap W, Pasqualini R, Sage EH.

J Biol Chem. 2010 Feb 19;285(8):5868-77. doi: 10.1074/jbc.M109.070318. Epub 2009 Dec 15.

21.

Cracking the code for compartment-specific dual functionality proteins in cancer: the case for CRKL.

Ozawa MG, Cardó-Vila M, Mintz PJ, Arap W, Pasqualini R.

Cell Cycle. 2010 Jan 1;9(1):8-9. Epub 2010 Jan 9. No abstract available.

PMID:
20009577
22.

An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment.

Mintz PJ, Cardó-Vila M, Ozawa MG, Hajitou A, Rangel R, Guzman-Rojas L, Christianson DR, Arap MA, Giordano RJ, Souza GR, Easley J, Salameh A, Oliviero S, Brentani RR, Koivunen E, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2009 Feb 17;106(7):2182-7. doi: 10.1073/pnas.0807543105. Epub 2009 Jan 23.

23.

A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11.

Cardó-Vila M, Zurita AJ, Giordano RJ, Sun J, Rangel R, Guzman-Rojas L, Anobom CD, Valente AP, Almeida FC, Lahdenranta J, Kolonin MG, Arap W, Pasqualini R.

PLoS One. 2008;3(10):e3452. doi: 10.1371/journal.pone.0003452. Epub 2008 Oct 20.

24.

A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications.

Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R.

J Immunol. 2007 Jun 15;178(12):8183-94.

25.

Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC.

Kzhyshkowska J, Workman G, Cardó-Vila M, Arap W, Pasqualini R, Gratchev A, Krusell L, Goerdt S, Sage EH.

J Immunol. 2006 May 15;176(10):5825-32.

26.

Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.

Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R.

Cancer Res. 2006 Jan 1;66(1):34-40.

27.

Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors.

Giordano RJ, Anobom CD, Cardó-Vila M, Kalil J, Valente AP, Pasqualini R, Almeida FC, Arap W.

Chem Biol. 2005 Oct;12(10):1075-83.

28.

SPARC regulates extracellular matrix organization through its modulation of integrin-linked kinase activity.

Barker TH, Baneyx G, Cardó-Vila M, Workman GA, Weaver M, Menon PM, Dedhar S, Rempel SA, Arap W, Pasqualini R, Vogel V, Sage EH.

J Biol Chem. 2005 Oct 28;280(43):36483-93. Epub 2005 Aug 22.

29.

Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer.

Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, Arap W.

Cancer Res. 2004 Jan 15;64(2):435-9.

30.

Alpha v beta 5 integrin-dependent programmed cell death triggered by a peptide mimic of annexin V.

Cardó-Vila M, Arap W, Pasqualini R.

Mol Cell. 2003 May;11(5):1151-62.

31.

Peptides targeting caspase inhibitors.

Tamm I, Trepel M, Cardó-Vila M, Sun Y, Welsh K, Cabezas E, Swatterthwait A, Arap W, Reed JC, Pasqualini R.

J Biol Chem. 2003 Apr 18;278(16):14401-5. Epub 2003 Jan 21.

32.

Is annexin 7 a tumor suppressor gene in prostate cancer?

Cardó-Vila M, Arden KC, Cavenee WK, Pasqualini R, Arap W.

Pharmacogenomics J. 2001;1(2):92-4. No abstract available.

PMID:
11911446
33.

Steps toward mapping the human vasculature by phage display.

Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardó-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R.

Nat Med. 2002 Feb;8(2):121-7.

PMID:
11821895
34.

Biopanning and rapid analysis of selective interactive ligands.

Giordano RJ, Cardó-Vila M, Lahdenranta J, Pasqualini R, Arap W.

Nat Med. 2001 Nov;7(11):1249-53.

PMID:
11689892

Supplemental Content

Loading ...
Support Center